# EDGAR Filing Document

**Accession Number:** 0000352665
**File Stem:** 0000940400-26-014241
**Filing Date:** 2026-4
**Character Count:** 34788
**Document Hash:** 783377f5a9b29d2326bede3d3d1b1388
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000940400-26-014241.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0000940400-26-014241

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260227

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**PERIOD START**: 20261130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PRUDENTIAL SECTOR FUNDS, INC.
- **CENTRAL INDEX KEY:** 0000352665

**ORGANIZATION NAME:**
- **EIN:** 133071974
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-03175
- **FILM NUMBER:** 26887835

**BUSINESS ADDRESS:**
- **STREET 1:** 655 BROAD STREET
- **STREET 2:** 6TH FLOOR
- **CITY:** NEWARK
- **STATE:** NJ
- **ZIP:** 07102
- **BUSINESS PHONE:** (973) 802-5032

**MAIL ADDRESS:**
- **STREET 1:** 655 BROAD STREET
- **STREET 2:** 6TH FLOOR
- **CITY:** NEWARK
- **STATE:** NJ
- **ZIP:** 07102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRUDENTIAL SECTOR FUNDS INC d/b/a JENNISONDRYDEN SECTOR FUNDS
- **DATE OF NAME CHANGE:** 20090113

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRUDENTIAL SECTOR FUNDS INC
- **DATE OF NAME CHANGE:** 20080902

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JENNISON SECTOR FUNDS INC
- **DATE OF NAME CHANGE:** 20030716

## Series and Classes Contracts Data

### PGIM Jennison Health Sciences Fund (Series ID: S000004380)

| Class ID   | Class Name   | Ticker Symbol   |
|:---|:---|:---|
| C000012121 | Class A      | PHLAX           |
| C000012123 | Class C      | PHLCX           |
| C000012124 | Class Z      | PHSZX           |
| C000110073 | Class R      | PJHRX           |
| C000165347 | Class R6     | PHLQX           |

## Nport-Ex

### PGIM Jennison Health Sciences Fund

### Schedule of Investments (unaudited)
as of February 28, 2026

---

| | | |
|:---|:---|:---|
| **Description** | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Value** |
| **Long-Term Investments 92.4%** | **Long-Term Investments 92.4%** | **Long-Term Investments 92.4%** |
| **Common Stocks 92.3%** | **Common Stocks 92.3%** | **Common Stocks 92.3%** |
| **Biotechnology 40.9%** | **Biotechnology 40.9%** | **Biotechnology 40.9%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Abivax SA (France), ADR\* | &nbsp;&nbsp;&nbsp;&nbsp;45200 | &nbsp;&nbsp; $5481856 |
| &nbsp;&nbsp;&nbsp;&nbsp;Apellis Pharmaceuticals, Inc.\* | &nbsp;&nbsp;&nbsp;594859 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12468245 |
| &nbsp;&nbsp;&nbsp;&nbsp;Apogee Therapeutics, Inc.\*(a) | &nbsp;&nbsp;&nbsp;240387 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16827090 |
| &nbsp;&nbsp;&nbsp;&nbsp;Arcutis Biotherapeutics, Inc.\* | &nbsp;&nbsp;&nbsp;391457 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10557595 |
| &nbsp;&nbsp;&nbsp;&nbsp;Argenx SE (Netherlands), ADR\* | &nbsp;&nbsp;&nbsp;&nbsp;59035 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45275122 |
| &nbsp;&nbsp;&nbsp;&nbsp;BeOne Medicines Ltd., ADR\* | &nbsp;&nbsp;&nbsp;&nbsp;87672 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27791147 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cabaletta Bio, Inc.\* | 3518102 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11680099 |
| &nbsp;&nbsp;&nbsp;&nbsp;Celcuity, Inc.\* | &nbsp;&nbsp;&nbsp;&nbsp;73339 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8192700 |
| &nbsp;&nbsp;&nbsp;&nbsp;Compass Pathways PLC (United Kingdom), ADR\* | &nbsp;&nbsp;&nbsp;610510 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4212519 |
| &nbsp;&nbsp;&nbsp;&nbsp;Disc Medicine, Inc.\* | &nbsp;&nbsp;&nbsp;198021 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13192159 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gilead Sciences, Inc. | &nbsp;&nbsp;&nbsp;427773 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63716788 |
| &nbsp;&nbsp;&nbsp;&nbsp;Immunovant, Inc.\* | &nbsp;&nbsp;&nbsp;277806 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7703560 |
| &nbsp;&nbsp;&nbsp;&nbsp;Insmed, Inc.\* | &nbsp;&nbsp;&nbsp;133269 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19901060 |
| &nbsp;&nbsp;&nbsp;&nbsp;Kymera Therapeutics, Inc.\* | &nbsp;&nbsp;&nbsp;215651 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19699719 |
| &nbsp;&nbsp;&nbsp;&nbsp;Mineralys Therapeutics, Inc.\* | &nbsp;&nbsp;&nbsp;403711 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11812584 |
| &nbsp;&nbsp;&nbsp;&nbsp;Newamsterdam Pharma Co. NV (Netherlands)\* | &nbsp;&nbsp;&nbsp;534102 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18939257 |
| &nbsp;&nbsp;&nbsp;&nbsp;Olema Pharmaceuticals, Inc.\* | &nbsp;&nbsp;&nbsp;344618 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8339756 |
| &nbsp;&nbsp;&nbsp;&nbsp;Palvella Therapeutics, Inc.\*(a) | &nbsp;&nbsp;&nbsp;183037 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24713656 |
| &nbsp;&nbsp;&nbsp;&nbsp;Protagonist Therapeutics, Inc.\* | &nbsp;&nbsp;&nbsp;135272 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12455846 |
| &nbsp;&nbsp;&nbsp;&nbsp;Regeneron Pharmaceuticals, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;57331 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44813923 |
| &nbsp;&nbsp;&nbsp;&nbsp;Revolution Medicines, Inc.\* | &nbsp;&nbsp;&nbsp;&nbsp;96874 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9883085 |
| &nbsp;&nbsp;&nbsp;&nbsp;Roivant Sciences Ltd.\* | 1022182 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29581947 |
| &nbsp;&nbsp;&nbsp;&nbsp;Scholar Rock Holding Corp.\* | &nbsp;&nbsp;&nbsp;524559 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23222227 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sionna Therapeutics, Inc.\*(a) | &nbsp;&nbsp;&nbsp;651048 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23789294 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tyra Biosciences, Inc.\* | &nbsp;&nbsp;&nbsp;182879 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6091699 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vaxcyte, Inc.\* | &nbsp;&nbsp;&nbsp;463089 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28591115 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vertex Pharmaceuticals, Inc.\* | &nbsp;&nbsp;&nbsp;104411 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;51874517 |
| &nbsp;&nbsp;&nbsp;&nbsp;Viridian Therapeutics, Inc.\* | &nbsp;&nbsp;&nbsp;459360 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13495997 |
| &nbsp;&nbsp;&nbsp;&nbsp;Xenon Pharmaceuticals, Inc. (Canada)\* | &nbsp;&nbsp;&nbsp;522446 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22585340 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;596889902 |
| **Health Care Services 3.3%** | **Health Care Services 3.3%** | **Health Care Services 3.3%** |
| &nbsp;&nbsp;&nbsp;&nbsp;CVS Health Corp. | &nbsp;&nbsp;&nbsp;597350 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47728265 |
| **Health Care Equipment 2.4%** | **Health Care Equipment 2.4%** | **Health Care Equipment 2.4%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Edwards Lifesciences Corp.\* | &nbsp;&nbsp;&nbsp;263382 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22774641 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tandem Diabetes Care, Inc.\* | &nbsp;&nbsp;&nbsp;496296 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12556289 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35330930 |
| **Health Care Supplies 0.8%** | **Health Care Supplies 0.8%** | **Health Care Supplies 0.8%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Align Technology, Inc.\* | &nbsp;&nbsp;&nbsp;&nbsp;60913 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11579561 |
| **Life Sciences Tools & Services 10.7%** | **Life Sciences Tools & Services 10.7%** | **Life Sciences Tools & Services 10.7%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Agilent Technologies, Inc. | &nbsp;&nbsp;&nbsp;202903 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24628366 |
| &nbsp;&nbsp;&nbsp;&nbsp;Danaher Corp. | &nbsp;&nbsp;&nbsp;210865 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44416604 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lonza Group AG (Switzerland) | &nbsp;&nbsp;&nbsp;&nbsp;65672 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45677700 |
| &nbsp;&nbsp;&nbsp;&nbsp;Thermo Fisher Scientific, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;78063 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40679410 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;155402080 |
| **Managed Health Care 4.3%** | **Managed Health Care 4.3%** | **Managed Health Care 4.3%** |
| &nbsp;&nbsp;&nbsp;&nbsp;UnitedHealth Group, Inc. | &nbsp;&nbsp;&nbsp;214171 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;62809929 |
| **Pharmaceuticals 29.9%** | **Pharmaceuticals 29.9%** | **Pharmaceuticals 29.9%** |
| &nbsp;&nbsp;&nbsp;&nbsp;AstraZeneca PLC (United Kingdom) | &nbsp;&nbsp;&nbsp;&nbsp;79048 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16477556 |
| &nbsp;&nbsp;&nbsp;&nbsp;Bayer AG (Germany) | &nbsp;&nbsp;&nbsp;306092 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15145690 |
| &nbsp;&nbsp;&nbsp;&nbsp;Crinetics Pharmaceuticals, Inc.\* | &nbsp;&nbsp;&nbsp;357533 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14694606 |

---

------

### PGIM Jennison Health Sciences Fund

### Schedule of Investments (unaudited) (continued)
as of February 28, 2026

---

| | | |
|:---|:---|:---|
| **Description** | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Value** |
| **Common Stocks (Continued)** | **Common Stocks (Continued)** | **Common Stocks (Continued)** |
| **Pharmaceuticals (cont'd.)** | **Pharmaceuticals (cont'd.)** | **Pharmaceuticals (cont'd.)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Eli Lilly & Co. | 232558 | &nbsp;&nbsp; $244648690 |
| &nbsp;&nbsp;&nbsp;&nbsp;LB Pharmaceuticals, Inc.\*(a) | 231150 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5549911 |
| &nbsp;&nbsp;&nbsp;&nbsp;Merck & Co., Inc. | 708913 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;87777608 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tarsus Pharmaceuticals, Inc.\* | 162644 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12282875 |
| &nbsp;&nbsp;&nbsp;&nbsp;Teva Pharmaceutical Industries Ltd. (Israel), ADR\* | 835523 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28290809 |
| &nbsp;&nbsp;&nbsp;&nbsp;UCB SA (Belgium) | &nbsp;&nbsp;36522 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10970603 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;435838348 |
| **Total Common Stocks<br> (cost $850,206,668)** | **Total Common Stocks<br> (cost $850,206,668)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1345579015 |

---

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**Units** |  |
| **Warrants\* 0.1%** | **Warrants\* 0.1%** | **Warrants\* 0.1%** |
| **Biotechnology** | **Biotechnology** | **Biotechnology** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cabaletta Bio, Inc., expiring 09/11/26<br> (cost $0) | 2139298 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1754224 |
| **Total Long-Term Investments<br> (cost $850,206,668)** | **Total Long-Term Investments<br> (cost $850,206,668)** | &nbsp;&nbsp;&nbsp;&nbsp;1347333239 |

---

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**Shares** |  |
| **Short-Term Investments 9.0%** | **Short-Term Investments 9.0%** | **Short-Term Investments 9.0%** |
| **Affiliated Mutual Funds** | **Affiliated Mutual Funds** | **Affiliated Mutual Funds** |
| &nbsp;&nbsp;&nbsp;&nbsp;PGIM Core Government Money Market Fund (7-day effective yield 3.787%)(wb) | &nbsp;&nbsp;107474012 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;107474012 |
| &nbsp;&nbsp;&nbsp;&nbsp;PGIM Institutional Money Market Fund (7-day effective yield 3.836%)<br> (cost $23,574,019; includes $23,536,891 of cash collateral for securities on loan)(b)(wb) | &nbsp;&nbsp;&nbsp;23590392 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23573879 |
| **Total Short-Term Investments<br> (cost $131,048,031)** | **Total Short-Term Investments<br> (cost $131,048,031)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;131047891 |
| **TOTAL INVESTMENTS 101.4%<br> (cost $981,254,699)** | **TOTAL INVESTMENTS 101.4%<br> (cost $981,254,699)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1478381130 |
| Liabilities in excess of other assets (1.4)% | Liabilities in excess of other assets (1.4)% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(20360365) |
| **Net Assets 100.0%** | **Net Assets 100.0%** | &nbsp;&nbsp;&nbsp;&nbsp;$1458020765 |

---

------

Below is a list of the abbreviation(s) used in the quarterly schedule of portfolio holdings:

 <br> ADR—American Depositary Receipt

\* Non-income producing security.

(a) All or a portion of security is on loan. The aggregate market value of such securities, including those sold and pending settlement, is $22,427,561; cash collateral of $23,536,891 (included in liabilities) was received with which the Fund purchased highly liquid short-term investments. In the event of significant appreciation in value of securities on loan on the last business day of the reporting period, the Fund may reflect a collateral value that is less than the market value of the loaned securities and such shortfall is remedied the following business day.

(b) Represents security, or portion thereof, purchased with cash collateral received for securities on loan and includes dividend reinvestment.

(wb) Represents an investment in a Fund affiliated with the Manager.

Other information regarding the Fund is available in the Fund's most recent Report to Shareholders. This information is available on the Securities and Exchange Commission's website (www.sec.gov).

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Prudential Sector Funds, Inc.

- **b. Investment Company Act file number:** 811-03175

- **c. CIK number of Registrant:** 0000352665

- **d. LEI of Registrant:** 549300IPCXL88G4QUI19

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 655 Broad Street

  - **City:** Newark

  - **State:** NJ

  - **Foreign country:** US

  - **Zip / Postal Code:** 07102-4077

  - **Telephone number:** 1-800-225-1852

**Item A.2. Information about the Series.**

- **a. Name of Series:** PGIM Jennison Health Sciences Fund

- **b. EDGAR series identifier (if any):** S000004380

- **c. LEI of Series:** S41LI155RNUZ4KJ9CN75

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-11-30

- **b. Date as of which information is reported:** 2026-02-27

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1488676958.95

**Total Liabilities:** $29703843.07

**Net Assets:** $1458973115.88

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000012121 | -2.19%               | -1.69%               | 2.21%                |
| Class ID C000012123 | -2.24%               | -1.74%               | 2.08%                |
| Class ID C000012124 | -2.16%               | -1.66%               | 2.21%                |
| Class ID C000110073 | -2.21%               | -1.71%               | 2.15%                |
| Class ID C000165347 | -2.16%               | -1.64%               | 2.23%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $85949118.86             | $-119449585.70                             |
| Month 2  | $38724683.31             | $-62454233.42                              |
| Month 3  | $15538921.86             | $16266451.63                               |

### Schedule of Portfolio Investments

| Name                                             | Title                                               | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| NewAmsterdam Pharma Company NV                   | NewAmsterdam Pharma Company NV ORDINARY SHARES      | CUSIP: 000000000<br>LEI: 984500B6549TF6E14D36 | Long             | EC               | CORP              | NL        |    534102 | NS      | $18939256.92  | 1.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Viridian Therapeutics Inc                        | Viridian Therapeutics Inc COM                       | CUSIP: 92790C104<br>LEI: 549300C775BNYF550E70 | Long             | EC               | CORP              | US        |    459360 | NS      | $13495996.80  | 0.93%             |  |  |  | No            |                  1 | On Loan: No      |
| Palvella Therapeutics Inc.                       | Palvella Therapeutics Inc. COM                      | CUSIP: 697947109<br>LEI: 254900AJDH8PAOOI5T33 | Long             | EC               | CORP              | US        |    183037 | NS      | $24713655.74  | 1.69%             |  |  |  | No            |                  1 | On Loan: —       |
| Cabaletta Bio Inc                                | Cabaletta Bio Inc COM                               | CUSIP: 12674W109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   3518102 | NS      | $11680098.64  | 0.80%             |  |  |  | No            |                  1 | On Loan: No      |
| Tandem Diabetes Care Inc                         | Tandem Diabetes Care Inc COM NEW                    | CUSIP: 875372203<br>LEI: 549300JEPFOD0K4D3I05 | Long             | EC               | CORP              | US        |    496296 | NS      | $12556288.80  | 0.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                                        | Argenx SE SPONSORED ADR                             | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     59035 | NS      | $45275122.20  | 3.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Apogee Therapeutics Inc.                         | Apogee Therapeutics Inc. COM                        | CUSIP: 03770N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    240387 | NS      | $16827090.00  | 1.15%             |  |  |  | No            |                  1 | On Loan: —       |
| Thermo Fisher Scientific Inc                     | Thermo Fisher Scientific Inc COM                    | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |     78063 | NS      | $40679409.93  | 2.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Align Technology Inc.                            | Align Technology Inc. COM                           | CUSIP: 016255101<br>LEI: 549300N5YSE0U3LCP840 | Long             | EC               | CORP              | US        |     60913 | NS      | $11579561.30  | 0.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Mineralys Therapeutics Inc.                      | Mineralys Therapeutics Inc. COM                     | CUSIP: 603170101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    403711 | NS      | $11812583.86  | 0.81%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc                         | Revolution Medicines Inc COM                        | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |     96874 | NS      | $9883085.48   | 0.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Crinetics Pharmaceuticals Inc.                   | Crinetics Pharmaceuticals Inc. COM                  | CUSIP: 22663K107<br>LEI: 549300Q1CNFXK5P31D28 | Long             | EC               | CORP              | US        |    357533 | NS      | $14694606.30  | 1.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Compass Pathways plc                             | Compass Pathways plc SPONSORED ADS                  | CUSIP: 20451W101<br>LEI: 213800N7CUZIC6QSTZ31 | Long             | EC               | CORP              | GB        |    610510 | NS      | $4212519.00   | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Disc Medicine Inc                                | Disc Medicine Inc COM                               | CUSIP: 254604101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    198021 | NS      | $13192159.02  | 0.90%             |  |  |  | No            |                  1 | On Loan: No      |
| LB Pharmaceuticals Inc.                          | LB Pharmaceuticals Inc. COM SHS                     | CUSIP: 50180M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    231150 | NS      | $5549911.50   | 0.38%             |  |  |  | No            |                  1 | On Loan: —       |
| Immunovant Inc                                   | Immunovant Inc COM                                  | CUSIP: 45258J102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    277806 | NS      | $7703560.38   | 0.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Apellis Pharmaceuticals Inc                      | Apellis Pharmaceuticals Inc COM                     | CUSIP: 03753U106<br>LEI: 254900HS0ZFRXXSB9D42 | Long             | EC               | CORP              | US        |    594859 | NS      | $12468244.64  | 0.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Tarsus Pharmaceuticals Inc                       | Tarsus Pharmaceuticals Inc COM                      | CUSIP: 87650L103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    162644 | NS      | $12282874.88  | 0.84%             |  |  |  | No            |                  1 | On Loan: No      |
| Kymera Therapeutics Inc                          | Kymera Therapeutics Inc COM                         | CUSIP: 501575104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    215651 | NS      | $19699718.85  | 1.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Uniqure N.V.                                     | Uniqure N.V. COM EUR0.05                            | CUSIP: 000000000<br>LEI: 724500RPCTZLFYJZ3S98 | Long             | EC               | CORP              | NL        |    228413 | NS      | $3570095.19   | 0.24%             |  |  |  | No            |                  1 | On Loan: No      |
| CVS Health Corp                                  | CVS Health Corp COM                                 | CUSIP: 126650100<br>LEI: 549300EJG376EN5NQE29 | Long             | EC               | CORP              | US        |    597350 | NS      | $47728265.00  | 3.27%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corporation                              | Danaher Corporation COM                             | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |    210865 | NS      | $44416603.60  | 3.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Celcuity Inc.                                    | Celcuity Inc. COM                                   | CUSIP: 15102K100<br>LEI: 25490070W7UU7W2SEY87 | Long             | EC               | CORP              | US        |     73339 | NS      | $8192699.69   | 0.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Tyra Biosciences Inc                             | Tyra Biosciences Inc COM                            | CUSIP: 90240B106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    182879 | NS      | $6091699.49   | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc.                          | UnitedHealth Group Inc. COM                         | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |    214171 | NS      | $62809929.17  | 4.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Protagonist Therapeutics Inc                     | Protagonist Therapeutics Inc COM                    | CUSIP: 74366E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    135272 | NS      | $12455845.76  | 0.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Incorporated              | Vertex Pharmaceuticals Incorporated COM             | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |    104411 | NS      | $51874517.13  | 3.56%             |  |  |  | No            |                  1 | On Loan: No      |
| (PIPA070) PGIM Core Government Money Market Fund | (PIPA070) PGIM Core Government Money Market Fund    | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | RF                | US        | 112597990 | NS      | $112597989.96 | 7.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Sionna Therapeutics Inc.                         | Sionna Therapeutics Inc. COM                        | CUSIP: 829401108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    651048 | NS      | $23789293.92  | 1.63%             |  |  |  | No            |                  1 | On Loan: —       |
| Gilead Sciences Inc.                             | Gilead Sciences Inc. COM                            | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    427773 | NS      | $63716788.35  | 4.37%             |  |  |  | No            |                  1 | On Loan: No      |
| Bayer AG                                         | Bayer AG NPV (REGD)                                 | CUSIP: 000000000<br>LEI: 549300J4U55H3WP1XT59 | Long             | EC               | CORP              | DE        |    306092 | NS      | $15145689.62  | 1.04%             |  |  |  | No            |                  2 | On Loan: No      |
| Regeneron Pharmaceuticals, Inc.                  | Regeneron Pharmaceuticals, Inc. COM                 | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |     57331 | NS      | $44813922.77  | 3.07%             |  |  |  | No            |                  1 | On Loan: No      |
| CABALETTA BIO INC WARRANT                        | CABALETTA BIO INC WARRANT                           | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2139298 | NS      | $1754224.36   | 0.12%             |  |  |  | No            |                  2 | On Loan: No      |
| Insmed Inc                                       | Insmed Inc COM PAR $.01                             | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |    133269 | NS      | $19901059.77  | 1.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Abivax SA                                        | Abivax SA SPONSORED ADS                             | CUSIP: 00370M103<br>LEI: 969500D8TMNB184OJU95 | Long             | EC               | CORP              | FR        |     45200 | NS      | $5481856.00   | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                                           | UCB SA NPV                                          | CUSIP: 000000000<br>LEI: 2138008J191VLSGY5A09 | Long             | EC               | CORP              | BE        |     36522 | NS      | $10970602.68  | 0.75%             |  |  |  | No            |                  2 | On Loan: No      |
| Agilent Technologies Inc.                        | Agilent Technologies Inc. COM                       | CUSIP: 00846U101<br>LEI: QUIX8Y7A2WP0XRMW7G29 | Long             | EC               | CORP              | US        |    202903 | NS      | $24628366.14  | 1.69%             |  |  |  | No            |                  1 | On Loan: No      |
| PRUDENTIAL INVESTMENT PORTFOLIOS 9               | Prudential Investment Portfolios 2 PGIM INSTL MONEY | CUSIP: 74440E300<br>LEI: 5493006TC8ECBK1GPV34 | Long             | EC               | RF                | US        |  23026544 | NS      | $23010425.78  | 1.58%             |  |  |  | No            |                  1 | On Loan: No      |
| BEONE MEDICINES LTD                              | BeOne Medicines Ltd. SPONSORED ADS                  | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | CH        |     87672 | NS      | $27791147.28  | 1.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Olema Pharmaceuticals Inc.                       | Olema Pharmaceuticals Inc. COM                      | CUSIP: 68062P106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    344618 | NS      | $8339755.60   | 0.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcutis Biotherapeutics Inc.                     | Arcutis Biotherapeutics Inc. COM                    | CUSIP: 03969K108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    391457 | NS      | $10557595.29  | 0.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Edwards Lifesciences Corporation                 | Edwards Lifesciences Corporation COM                | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |    263382 | NS      | $22774641.54  | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co., Inc                                 | Merck & Co., Inc COM                                | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    708913 | NS      | $87777607.66  | 6.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Lonza Group AG                                   | Lonza Group AG CHF1 (REGD)                          | CUSIP: 000000000<br>LEI: 549300EFW4H2TCZ71055 | Long             | EC               | CORP              | CH        |     65672 | NS      | $45677700.19  | 3.13%             |  |  |  | No            |                  2 | On Loan: No      |
| Roivant Sciences Ltd                             | Roivant Sciences Ltd SHS                            | CUSIP: 000000000<br>LEI: 549300DL466NY5J6U724 | Long             | EC               | CORP              | BM        |   1022182 | NS      | $29581947.08  | 2.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Teva Pharmaceutical Industries Ltd.              | Teva Pharmaceutical Industries Ltd. SPONSORED ADS   | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |    835523 | NS      | $28290808.78  | 1.94%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                                  | AstraZeneca PLC ORD USD0.25                         | CUSIP: 000000000<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |     79048 | NS      | $16477555.60  | 1.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Xenon Pharmaceuticals Inc                        | Xenon Pharmaceuticals Inc COM                       | CUSIP: 98420N105<br>LEI: 549300XV44Q9Z1MIPQ03 | Long             | EC               | CORP              | CA        |    522446 | NS      | $22585340.58  | 1.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Scholar Rock Holding Corp.                       | Scholar Rock Holding Corp. COM                      | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |    524559 | NS      | $23222226.93  | 1.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co.                                  | Eli Lilly & Co. COM                                 | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    232558 | NS      | $244648690.42 | 16.77%            |  |  |  | No            |                  1 | On Loan: No      |
| Vaxcyte Inc                                      | Vaxcyte Inc COM                                     | CUSIP: 92243G108<br>LEI: 254900M7NMHTGASX8D95 | Long             | EC               | CORP              | US        |    463089 | NS      | $28591114.86  | 1.96%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-04-23

**Name of Applicant:** Prudential Sector Funds, Inc.

**Signature:** Christian J. Kelly

**Name of Signer:** Christian J. Kelly

**Title:** Chief Financial Officer